Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that the therapy “improves inflammation and rapidly supresses IL-23” in cases of the disease.
Published in the Journal of Allergy and Clinical Immunology, the findings indicated that Consentyx generated a “substantial improvement” in inflammation for the majority of patients after as little as 12 weeks by modulating gene expression and reversing plaque histopathology.
